Ftse Mib
34.165,92
0,01%
DAX
19.909,14
-0,25%
S&P 500
5.922,00
-0,82%
NASDAQ
19.511,54
-1,07%
Bitcoin
92.023,30
-1,59%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ REGENXBIO Inc (RGNX) REGENXBIO Inc (RGNX) Notizie

REGENXBIO Inc

RGNX
7,35
-0,06 (-0,81%)
Ultimo aggiornamento: 17:46:31
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/12/202423:12EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/12/202422:45EDGAR2Form 8-K - Current report
07/12/202400:29PRNUSApollo Global Management and Workday Set to Join S&P 500;..
14/11/202413:05PRNUSREGENXBIO to Host Webcast Discussing Pivotal Program and..
06/11/202422:10EDGAR2Form 8-K - Current report
06/11/202422:05PRNUSREGENXBIO Reports Third Quarter 2024 Financial Results and..
04/11/202413:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
30/10/202412:05PRNUSREGENXBIO to Host Conference Call on November 6 to Discuss..
21/10/202413:05PRNUSREGENXBIO Presents Positive Data from the Phase II Study of..
18/10/202413:05PRNUSREGENXBIO Announces Presentations at the American Academy of..
23/9/202422:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
18/9/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/9/202423:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
17/9/202423:00EDGAR2Form 8-K - Current report
17/9/202413:05PRNUSREGENXBIO Appoints Mitchell Chan as Chief Financial Officer
03/9/202414:04PRNUSREGENXBIO Announces Positive Data from Pivotal Dose Level of..
29/8/202422:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
27/8/202413:05PRNUSREGENXBIO Announces Presentation at the Society for the..
12/8/202422:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202413:05PRNUSREGENXBIO to Participate in the H.C. Wainwright 4th Annual..
06/8/202400:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/8/202400:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/8/202422:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202422:10EDGAR2Form 8-K - Current report
01/8/202422:05PRNUSREGENXBIO Reports Second Quarter 2024 Financial Results and..
01/8/202413:03PRNUSREGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY..
26/7/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/7/202413:05PRNUSREGENXBIO to Host Conference Call on August 1 to Discuss..
18/7/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/6/202413:05PRNUSREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to..
18/6/202413:05PRNUSREGENXBIO Announces Successful Pre-BLA Meeting with FDA to..
12/6/202413:05PRNUSREGENXBIO Announces Leadership Transition
05/6/202413:05PRNUSREGENXBIO to Participate in the Goldman Sachs 45th Annual..
04/6/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202422:35EDGAR2Form 8-K - Current report
16/5/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:22EDGAR2Form 144 - Report of proposed sale of securities
10/5/202413:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
08/5/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:10EDGAR2Form 8-K - Current report
08/5/202422:05PRNUSREGENXBIO Reports First Quarter 2024 Financial Results and..
01/5/202413:05PRNUSREGENXBIO to Host Conference Call on May 8 to Discuss First..
24/4/202413:05PRNUSREGENXBIO to Participate in Chardan's 8th Annual Genetic..
28/3/202412:05PRNUSREGENXBIO Announces Lancet Publication of Phase I/IIa Study..
27/3/202421:05PRNUSREGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD..
11/3/202413:00EDGAR2Form 8-K - Current report
11/3/202412:05PRNUSREGENXBIO to Participate in Upcoming Investor Conferences
Apertura: 7,35 Min: 7,20 Max: 7,50
Chiusura: 7,41

La tua Cronologia

NASDAQ
RGNX
REGENXBIO
BIT
NSCIT2694866
Agricultural Pension Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network